Biosimilar Safety in 2025 | Your Strategic Pharmacovigilance Checklist

📢 DDReg Knowledge Capsule – Episode [6]Strategic Pharmacovigilance Checklist for Biosimilar Safety in 2025," which offers guidance on managing the increasing complexities of biosimilar safety. The article explains that the biosimilar market is rapidly expanding, necessitating robust pharmacovigilance (PV) to ensure patient safety and mitigate risks. It presents a comprehensive checklist covering key areas such as creating unique Risk Management Plans (RMPs), prioritizing immunogenicity oversight, ensuring detailed traceability and product identification, and employing advanced signal detection techniques using AI/ML tools.